Juno Therapeutics develops cell-based cancer immunotherapies based on its chimeric antigen receptor and T cell receptor technologies to genetically engineer T cells to recognize and kill cancer cells. The Company is exploring the potential of its CAR and TCR technologies against targets that have the potential to treat cancers beyond B cell malignancies and multiple myeloma, in particular, difficult-to-treat solid organ tumors, such as certain breast, lung and pancreatic cancers.
Type
Public
Parent Company
Celgene Corporation
HQ
Seattle, US
Founded
2013
Size (employees)
589 (est)
Juno Therapeutics was founded in 2013 and is headquartered in Seattle, US
Report incorrect company information

Key People/Management at Juno Therapeutics

Hans Bishop

Hans Bishop

CEO
Hyam Levitsky

Hyam Levitsky

EVP, Chief Scientific Officer
Steve Harr

Steve Harr

CFO & Head of Corporate Development
Bob Azelby

Bob Azelby

EVP, Chief Commercial Officer
Cindy Elkins

Cindy Elkins

Chief Information Officer
Mark Gilbert

Mark Gilbert

SVP, Chief Medical Officer
Show more

Juno Therapeutics Office Locations

Juno Therapeutics has offices in München, Göttingen, Waltham, Bothell and in 2 other locations
Seattle, US (HQ)
300 307 Westlake Ave N
Bothell, US
18333 120th Ave NE
Brisbane, US
2000 Sierra Point Pkwy
Waltham, US
950 Winter St
Göttingen, DE
28 Rudolf-Wissell-Straße
München, DE
10 Grillparzerstraße
Show all (6)
Report incorrect company information

Juno Therapeutics Financials and Metrics

Juno Therapeutics Financials

Juno Therapeutics's revenue was reported to be $79.36 m in FY, 2016 which is a 335.7% increase from the previous period.
USD

Revenue (Q3, 2017)

44.8 m

Net income (Q3, 2017)

(118.1 m)

EBIT (Q3, 2017)

(121.8 m)

Market capitalization (26-Feb-2018)

9.1 b

Cash (30-Sep-2017)

449.8 m
Juno Therapeutics's current market capitalization is $9.1 b.
Annual
USDFY, 2015FY, 2016

Revenue

18.2 m79.4 m

Revenue growth, %

336%

General and administrative expense

4.2 m70.7 m

R&D expense

46.2 m264.3 m
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Revenue

12.5 m1.6 m9.8 m27.6 m20.8 m19.3 m21.3 m44.8 m

General and administrative expense

6.7 m14.9 m13.6 m16 m16.8 m18.4 m20.7 m23.6 m26.3 m

R&D expense

57.8 m60.2 m11.5 m73.7 m72.3 m60.9 m82.9 m101.1 m140.3 m

Operating expense total

65.2 m80.4 m25.1 m89.7 m89.1 m79.3 m103.7 m124.7 m166.6 m
Annual
USDFY, 2015FY, 2016

Cash

252.4 m187.9 m

Accounts Receivable

315 k13.3 m

Inventories

8.4 m26.5 m

Current Assets

951.8 m772.3 m
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

164.2 m39.5 m569.1 m316 m285.3 m223.4 m205.7 m218.7 m449.8 m

Accounts Receivable

9.3 m10.6 m8.8 m10.4 m34.3 m

Current Assets

400.7 m307.8 m1.2 b956 m974.6 m844.8 m779.5 m736.6 m972.5 m

PP&E

15.4 m28.7 m36.9 m45 m51.5 m57.7 m102.5 m124.3 m131.6 m
Annual
USDFY, 2015FY, 2016

Net Income

(51.8 m)(245.6 m)

Depreciation and Amortization

2 k14.2 m

Accounts Payable

(2.7 m)3.7 m

Cash From Operating Activities

(103.6 m)(189.8 m)
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(65 m)(66 m)(23.2 m)(71.1 m)(64.8 m)(56.9 m)(82.2 m)

Depreciation and Amortization

1 m

Accounts Payable

(27 k)1.9 m3 m2.2 m3.2 m3.7 m3.2 m

Cash From Operating Activities

(21.6 m)
USDY, 2017

Revenue/Employee

76.1 k

Financial Leverage

1.3 x
Show all financial metrics

Juno Therapeutics Operating Metrics

Juno Therapeutics's Patent Applications was reported to be 481 in FY, 2016.
FY, 2016

Patent Applications

481

Patents (US)

72

Patents (foreign)

86
Show all operating metrics
Report incorrect company information

Juno Therapeutics News and Updates

Juno Therapeutics CEO Bishop set for $200M+ payday with Celgene buyout

Juno Therapeutics CEO Hans Bishop is in line for a nice payday when his company seals the deal with Celgene. Think $200 million or more.
Report incorrect company information